ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis

ÜRÜN, YÜKSEL; Leow, Jeffrey; Fay, Andre; Albiges, Laurence; Choueiri, Toni; Bellmunt, Joaquim

doi:10.1016/j.critrevonc.2017.10.012

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis

Atıf İçin Kopyala

ÜRÜN Y., Leow J. J., Fay A. P., Albiges L., Choueiri T. K., Bellmunt J.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, cilt.120, ss.120-126, 2017 (SCI-Expanded)

Yayın Türü: Makale / Derleme
Cilt numarası: 120
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.critrevonc.2017.10.012
Dergi Adı: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.120-126
Ankara Üniversitesi Adresli: Evet

Özet

Background: The predictive role of excision repair cross-complementing group 1 (ERCC1) as a predictive factor in patients with advanced urothelial cancer (AUC) treated with platinum-based treatment is not well defined. Here, we evaluate the role of ERCC1 in patients with AUC treated with platinum-based treatment.